The anti-hypoxia-A2-Adenosinergic immunotherapies of cancer emerged as the only available now approach to enable the tumor rejection in those progressing cancer patients that are refractory to all other current treatments. Several different classes of drugs are offered to inhibit the Hypoxia-HIF-1alpha-mediated and extracellular adenosine-A2A adenosine receptor-mediated immunosuppressive signaling in tumor microenvironment. It is suggested that the most promising treatments must include the blockade of cAMP-elevating A2A adenosine receptors and the elimination of hypoxia in tumors by oxygenation agents and hyperoxic breathing. The observations in ongoing clinical trials support this conclusion.

中文翻译：

---

足够数量的抗肿瘤 T 细胞是抗缺氧-A2-腺苷能药物在癌症免疫治疗期间发挥最大功效的条件。

癌症的抗缺氧-A2-腺苷能免疫疗法成为目前唯一可用的方法，可以在那些对所有其他当前治疗方法均无效的进展性癌症患者中实现肿瘤排斥。提供了几种不同类别的药物来抑制肿瘤微环境中缺氧-HIF-1α 介导的和细胞外腺苷-A2A 腺苷受体介导的免疫抑制信号传导。建议最有希望的治疗方法必须包括阻断 cAMP 升高的 A2A 腺苷受体，以及通过增氧剂和高氧呼吸消除肿瘤中的缺氧。正在进行的临床试验中的观察结果支持这一结论。